Physician profile
Jared D Acoba
NPI 1508889338
$14,911.43
in general payments reported to CMS, 2019-2025
52 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $162 · 2021: $1,319 · 2022: $5,386 · 2023: $1,797 · 2024: $4,292 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045 · Consulting Fee: $2,400 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.86 |
| Consulting Fee | $2,400.00 |
| Education | $208.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,018.86 | 2021-2025 | Imfinzi, Lynparza |
| Glaxosmithkline, LLC. | $2,480.82 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $766.08 | 2021-2025 | |
| Pfizer INC. | $630.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.51 | 2019-2025 | Ninlaro, Advate |
| Merck Sharp & Dohme LLC | $574.61 | 2020-2025 | Keytruda, Lenvima, Welireg |
| Eisai INC. | $521.53 | 2021-2025 | |
| Astellas Pharma US INC | $469.50 | 2021-2025 | Xtandi, Vyloy |
| Janssen Biotech, INC. | $449.74 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Incyte Corporation | $427.73 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $368.22 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $355.55 | 2020-2025 | Opdualag, Opdivo |
| Genzyme Corporation | $349.56 | 2021-2022 | |
| US Oncology Corporate, INC. | $329.80 | 2023-2024 | |
| Amgen INC. | $241.54 | 2021-2023 | Xgeva, Nplate, Lumakras |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Acoba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.